Results
8530
Companies with a Future performance score of at least 3, ordered by Future performance score.
8,530 companies
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
DOMS | ₹2,522.45 | 11.6% | 78.4% | ₹153.1b | ₹3,055.00 | PE82.4x | E22.7% | 0.1% | Commercial Services | ||
ACI | ₹586.85 | 3.8% | -5.3% | ₹72.4b | ₹826.00 | PE33x | E41.2% | 0.5% | Materials | ||
JYOTICNC | ₹1,030.35 | -8.7% | 75.8% | ₹234.3b | ₹1,450.00 | PE85.4x | E33.9% | n/a | Capital Goods | ||
PRICOLLTD | ₹511.50 | 1.5% | 25.1% | ₹62.3b | ₹590.00 | PE35.9x | E25.2% | 0% | Automobiles | ||
SKS | AU$2.21 | 2.8% | 662.1% | AU$247.7m | AU$2.15 | PE37.4x | E24.8% | 0.5% | Capital Goods | ||
FWRY | ج.م8.47 | -0.4% | 63.2% | ج.م29.3b | ج.م12.45 | PE23.3x | E27.4% | n/a | Diversified Financials | ||
CADLR | NOK 60.20 | 6.0% | 24.8% | NOK 21.1b | NOK 81.81 | PE197.4x | E70.7% | n/a | Capital Goods | ||
RMDA | ج.م3.73 | 11.3% | 57.4% | ج.م5.4b | ج.م5.02 | PE21.1x | E30.7% | 1.8% | Pharmaceuticals & Biotech | ||
YGG | ฿0.65 | 3.2% | -90.5% | ฿391.3m | ฿10.75 | PS1.8x | E87.1% | 41.2% | Media | ||
AFISH | NOK 67.50 | 3.1% | 12.5% | NOK 2.2b | NOK 81.00 | PE65.7x | E65.4% | n/a | Food, Beverage & Tobacco | ||
AXSM | US$106.46 | 3.7% | 16.3% | US$5.2b | US$135.13 | PS15.2x | E58.0% | n/a | Pharmaceuticals & Biotech | ||
ELABS | NOK 11.36 | 8.2% | -32.1% | NOK 1.2b | NOK 19.00 | PS12.8x | E121.1% | n/a | Software | ||
RHM | €755.40 | 4.5% | 130.7% | €32.8b | €769.79 | PE47.9x | E29.9% | 0.8% | Capital Goods | ||
PHM | €92.65 | 8.7% | 149.9% | €1.6b | €86.40 | PE2592.7x | E44.7% | 0.7% | Pharmaceuticals & Biotech | ||
LAVV3 | R$8.68 | 5.3% | 12.9% | R$1.7b | R$12.65 | PE5.5x | E20.5% | 3.3% | Real Estate Management and Development | ||
PRL | CA$38.54 | -1.1% | 145.2% | CA$1.5b | CA$45.92 | PE23.8x | E38.9% | 1.6% | Diversified Financials | ||
ALNY | US$271.31 | -2.0% | 58.9% | US$35.0b | US$299.74 | PS16.7x | E56.7% | n/a | Pharmaceuticals & Biotech | ||
ARES | US$198.22 | 4.3% | 59.2% | US$62.1b | US$195.00 | PE92.6x | E38.4% | 1.9% | Diversified Financials | ||
KINS | US$16.99 | 15.6% | 436.0% | US$209.8m | US$18.00 | PE13.2x | E24.9% | 0% | Insurance | ||
TVTX | US$20.46 | 1.6% | 147.7% | US$1.8b | US$28.47 | PS8.8x | E62.1% | n/a | Pharmaceuticals & Biotech | ||
RCEL | US$9.10 | -2.4% | -45.5% | US$240.5m | US$17.08 | PS4x | E51.9% | n/a | Pharmaceuticals & Biotech | ||
ALKT | US$34.79 | -1.4% | 41.9% | US$3.5b | US$45.10 | PS11.1x | E102.7% | n/a | Software | ||
GAU | CA$1.60 | -1.8% | 33.3% | CA$411.3m | CA$3.12 | PS1.7x | E65.4% | n/a | Materials | ||
AGP | €5.60 | 0.7% | -27.1% | €97.0m | €12.85 | PE14.3x | E22.1% | n/a | Capital Goods |